There will be no buy out as there is nothing to buy, there are numerous CBD/THC pills out on the market with "metered" dosing and nothing stopping anyone from creating their own pill.
People throw out "buy-out" all the time on the OTC and it rarely happens and even less so for companies with no revenues or assets.
Fully diluted share count is about 1.2B currently and that excludes convertible debt.
So even with an insane purchase price of $30M, you'd take $1M off the top for payoff of debt and you'd end up with .024 a share, and what would someone actually be getting for that purchase price? Companies current assets are $200k and that includes $92k in loan receivable from related party PAOG, so there is nothing to buy and Cannophen is not anything to buy either as why would a company spend a lot of money for Cannophen when they could just make it themselves fora fraction of the cost?
News 
Market Data 
Discover 
